Navigation Links
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
Date:11/11/2013

LONDON, Nov. 11, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme (GBM).

Glioma describes any tumor that arises from the glial tissue of the brain. GBM is a particularly aggressive tumor that forms from abnormal growth of glial tissue. According to the New England Journal of Medicine, GBM accounts for approximately 50% of the 22,500 new cases of brain cancer diagnosed in the United States each year. Treatment options are limited and expected survival is a little over one year. GBM is considered a rare, or orphan, disease by the FDA and the European Medicines Agency, or EMA.

This study follows several years of pre-clinical research conducted by GW in the field of glioma which has demonstrated that cannabinoids inhibit the viability of glioma cells both in vitro and in vivoi,ii via apoptosis or programmed cell death, may also affect angiogenesis, and have demonstrated tumor growth-inhibiting action and an improvement in the therapeutic efficacy of temozolomide, a standard treatment for glioma. In addition, GW has shown tumor response to be positively associated with tissue levels of cannabinoids. GW has identified the putative mechanism of action for our cannabinoid product candidate, where autophagy and programmed cell death are stimulated via stimulation of the TRB3 pathway.

"We are very excited about moving this compound into further human study and the prospects of cannabinoids as new anti-cancer treatments. This is GW's first clinical study of cannabinoids as a potential treatment to inhibit tumor growth," stated Dr. Stephen Wri
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 According to a ... Cryogenic Storage Systems, Thawing Equipment, Alarms), by Biospecimen (Human ... Trials), End User - Global Forecast to 2020", published ... reach USD 3,731.03 Million by 2020 from USD 2,150.48 ... between 2015 and 2020. Browse 74 ...
(Date:8/28/2015)... ... ... initial launch of FireflySci Inc. (FFS) in early 2015, the company continues to shake up ... the Fonz in a lab coat and Large Marge have been posted on the company’s ... , FireflySci is proud to be the only cuvette manufacturer is the world that has ...
(Date:8/27/2015)... , Aug. 27, 2015 The ... a patient,s eyes—and life—were saved by doctors at Vanderbilt ... working with NNFF, NovaBay Pharmaceuticals and Dr. John ... Center at Seton Medical Center in ... treatment used a breakthrough approach, pioneered by Dr. Crew, ...
(Date:8/27/2015)... MA (PRWEB) , ... August 27, 2015 , ... Inc. ... United States, ranking iLab Solutions as number 1,361 in growth for the three years ... of the top 0.1% fastest-growing privately held organizations in the country. , “We ...
Breaking Biology Technology:Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
(Date:8/24/2015)...  Based on its recent analysis of the biometric products ... Biometrics Company of the Year Award. DERMALOG is the leading ... Africa . It has particularly gained prominence ... one of the largest biometric mass applications in the world, ... Bank of Nigeria with its biometric ...
(Date:8/20/2015)... OXFORD, CT ., Aug. 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... wallet, announces it has joined The Smart Card Alliance ... the Smart Card Alliance and the Smart Card Alliance ... and visibility to industry peers and thought leaders promoting ...
(Date:8/18/2015)... 17, 2015 Research and Markets ( ... "Global Biometric Authentication & Identification Market: Focus ... Forecast, 2015-2020" report to their offering. ... systems market is expected to grow at an ... and generate over $25 billion (approximately) by 2020 ...
Breaking Biology News(10 mins):Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... Not least because undifferentiated cells with features typical of ... the liver, brain, and muscles, scientists are beginning to ... organs. Researchers from the Max Planck Institute for Heart ... demonstrated, in a study published in the journal Molecular ...
... are published, including a new book entitled The Dog ... articles in the journal Genome Research . These ... a high-quality draft sequence of the dog genome, are expected ... about canine genomics and biology. , "Canine genetics has entered ...
... it be that the stress on the use of antiseptics ... greater risk of suffering fatal bacterial infection? , Yes, argues ... Center for the Study of Infectious and Tropical Diseases at ... points to a recent BBC report on the poor record ...
Cached Biology News:Forgotten by evolution? 2Dog genome sequenced 2Dog genome sequenced 3Dog genome sequenced 4'Good' bacteria could save patients from infection infection by deadlier ones 2
Rabbit polyclonal to Kallikrein 1 ( Abpromise for all tested applications). Antigen: Full length native kallikrein from tissue (Human) Entrez Gene ID: 3816 Swiss Protein ID: P06870...
PSGL-1 (215)...
Mouse Anti-human CD11b/Mac-1alpha, clone LM2/1, Monoclonal Antibody...
Mouse monoclonal [MLM544] to cardiac Myosin light chain 1 ( Abpromise for all tested applications). entrezGeneID: 4634 SwissProtID: P08590...
Biology Products: